Advanced Filters
noise

Cary, North Carolina Clinical Trials

A listing of Cary, North Carolina clinical trials actively recruiting patient volunteers.

Found 183 clinical trials
L Lauren Patrick

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. …

18 years of age Female Phase 3
J Jennifer Mellon

A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.

18 - 65 years of age All Phase 2
M Michele Frank

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is that in infertile woman with endometriosis undergoing in vitro fertilization-embryo transfer (IVF-ET), live birth rates will improve in those …

18 - 40 years of age Female Phase 3
J Jeff Bullock

A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The …

18 - 70 years of age All Phase 4
K Kylie Hampton

Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System

The H3 TAR Prosthesis was approved by FDA (P160036) on June 4, 2019. Continued approval of the premarket approval application (PMA) is contingent upon the submission of periodic reports (Annual Report), required under 21 CFR 814.84. In order to provide continued reasonable assurance of the safety and effectiveness of the …

21 years of age All Phase N/A

Bempedoic Acid Pregnancy Surveillance Program

Bempedoic acid pregnancy surveillance program

18 years of age Female Phase N/A
N NIEHS Join A Study Recruitment Group

Investigating the Impact of Obesity on Pubertal Development in Girls

Background Studies suggest that overweight girls may be developing breast tissue, and therefore starting puberty, earlier than normal weight girls. However, it is hard to distinguish breast tissue from fatty tissue. Researchers think that by using breast ultrasound, among other tests, they can do a better job of telling whether …

8 - 14 years of age Female Phase N/A
L Lori O'Brien

ATEMPT 2.0: Adjuvant T-DM1 vs TH

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two different combination of HER2-directed therapies as a treatment after surgery. The name of the study drugs involved are: Trastuzumab-emtansine (T-DM1, Kadcyla) Trastuzumab SC (Herceptin Hylecta) …

18 years of age All Phase 2
J Jordan Harmon

Patient Specific Talus Spacer Post Approval Study

Humanitarian Device Exemption Approved Patient Specific Talus Spacer Post Approval Study.

21 years of age All Phase N/A

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more …

18 - 89 years of age All Phase 2

Simplify language using AI